Literature DB >> 18468839

Nebulized furosemide for the management of dyspnea: does the evidence support its use?

Phillip J Newton1, Patricia M Davidson, Peter Macdonald, Richard Ollerton, Henry Krum.   

Abstract

Dyspnea is a common and distressing symptom associated with multiple chronic illnesses and high levels of burden for individuals, their families and health care systems. The subjective nature dyspnea and a poor understanding of pathophysiological mechanisms challenge the clinician in developing management plans. Nebulized furosemide has been identified as a novel approach to dyspnea management. This review summarizes published studies, both clinical and experimental, reporting the use of nebulized furosemide. The search criteria yielded 42 articles published in the period 1988 to 2004. Although nebulized furosemide appeared to have a positive influence on dyspnea and physiological measurements, caution must be taken with the results primarily coming from small-scale clinical trials or observation trials. Despite the limitations of the studies reported, given the range of conditions reporting effectiveness of nebulized furosemide, further investigation of this potential novel treatment of dyspnea is warranted.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18468839     DOI: 10.1016/j.jpainsymman.2007.10.017

Source DB:  PubMed          Journal:  J Pain Symptom Manage        ISSN: 0885-3924            Impact factor:   3.612


  7 in total

1.  Controlled Delivery of 80 mg Aerosol Furosemide Does Not Achieve Consistent Dyspnea Relief in Patients.

Authors:  Robert W Hallowell; Richard Schwartzstein; Carl R O'Donnell; Andrew Sheridan; Robert B Banzett
Journal:  Lung       Date:  2019-11-15       Impact factor: 2.584

Review 2.  Exercise therapy in the management of dyspnea in patients with cancer.

Authors:  Graeme J Koelwyn; Lee W Jones; Whitney Hornsby; Neil D Eves
Journal:  Curr Opin Support Palliat Care       Date:  2012-06       Impact factor: 2.302

Review 3.  Supportive and palliative care for lung cancer patients.

Authors:  Patsy Yates; Penelope Schofield; Isabella Zhao; David Currow
Journal:  J Thorac Dis       Date:  2013-10       Impact factor: 2.895

4.  Chloride transport-driven alveolar fluid secretion is a major contributor to cardiogenic lung edema.

Authors:  Esther A Solymosi; Stefanie M Kaestle-Gembardt; István Vadász; Liming Wang; Nils Neye; Cécile Julie Adrienne Chupin; Simon Rozowsky; Ramona Ruehl; Arata Tabuchi; Holger Schulz; Andras Kapus; Rory E Morty; Wolfgang M Kuebler
Journal:  Proc Natl Acad Sci U S A       Date:  2013-05-03       Impact factor: 11.205

5.  An online survey of Australian physicians reported practice with the off-label use of nebulised frusemide.

Authors:  Phillip J Newton; Patricia M Davidson; Christine Sanderson
Journal:  BMC Palliat Care       Date:  2012-04-30       Impact factor: 3.234

6.  Recent advances in the management of breathlessness.

Authors:  Katrina Breaden
Journal:  Indian J Palliat Care       Date:  2011-01

7.  Combination adjunctive nebulized furosemide and salbutamol versus single agent therapy in COPD patients: A randomized controlled trial.

Authors:  Mohammadali Saba; Abdoulhossein Davoodabadi; Azin Ghaffari; Hamidreza Gilasi; Babak Haghpanah
Journal:  Ann Med Surg (Lond)       Date:  2020-07-18
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.